Lanean...

Risk of cervical HPV infection and prevalence of vaccine-type and other high-risk HPV types among sexually active teens and young women (13–26 years) enrolled in the VALHIDATE study

HPV vaccination is expected to reduce the incidence of cervical cancer. The greatest and the earliest health gains will be ensured by high vaccine coverage among all susceptible people. The high costs and the risk of a reduced cost/effectiveness ratio in sexually active girls still represent the mai...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Hum Vaccin Immunother
Egile Nagusiak: Orlando, Giovanna, Fasolo, Michela, Mazza, Francesca, Ricci, Elena, Esposito, Susanna, Frati, Elena, Zuccotti, Gian Vincenzo, Cetin, Irene, Gramegna, Maria, Rizzardini, Giuliano, Tanzi, Elisabetta, group, VALHIDATE study
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Taylor & Francis 2014
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4896517/
https://ncbi.nlm.nih.gov/pubmed/24423757
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/hv.27682
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!